Skin Diseases  >>  Perjeta (pertuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
NCT00301899: Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Completed
2
37
US
pertuzumab, trastuzumab
National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI)
Breast Cancer
 
10/07
NCT01674062 / 2005-003493-19: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Completed
2
95
Canada, Europe
Pertuzumab, Perjeta, Trastuzumab, Herceptin
Hoffmann-La Roche
Breast Cancer
02/08
09/15
NCT00943670: Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Completed
2
51
US
pertuzumab, PERJETA™, Trastuzumab emtansine [Kadcyla], trastuzumab-MCC-DM1, T-DM1
Genentech, Inc.
Metastatic Breast Cancer
12/10
08/11
TRYPHAENA, NCT00976989 / 2009-012019-17: A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Checkmark
May 2013 - May 2013: 
Checkmark SG-BCC 2013
Mar 2013 - Mar 2013: SG-BCC 2013
Checkmark P2 data - ESMO
More
Completed
2
225
Canada, Europe, RoW
Pertuzumab, Perjeta, Trastuzumab, Herceptin, FEC, Docetaxel, TCH
Hoffmann-La Roche
Breast Cancer
06/11
01/16
NeoSphere, NCT00545688 / 2007-001105-13: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Checkmark NEOSPHERE trial in neoadjuvant breast cancer at ASCO 2015
May 2015 - Jun 2015: NEOSPHERE trial in neoadjuvant breast cancer at ASCO 2015
Checkmark Final PFS/DFS data from NEOSPHERE trial in neoadjuvant BC at ASCO 2015
May 2015 - May 2015: Final PFS/DFS data from NEOSPHERE trial in neoadjuvant BC at ASCO 2015
Checkmark For HER2 positive breast cancer in neoadjuvant setting
More
Completed
2
417
Canada, Europe, RoW
Herceptin, Trastuzumab, Docetaxel, Pertuzumab
Hoffmann-La Roche
Breast Cancer
09/14
09/14
NCT01565083 / 2011-003308-18: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Checkmark EBCC 2014
Mar 2014 - Mar 2014: EBCC 2014
Completed
2
213
US, Europe, RoW
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Vinorelbine
Hoffmann-La Roche
Breast Cancer
10/15
10/15
SOLTI-Opti-HER, NCT01669239 / 2012-001201-24: Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

Checkmark SG-BCC 2015
Mar 2015 - Mar 2015: SG-BCC 2015
Completed
2
83
Europe
Liposomal Doxorubicin, Myocet® (liposome-encapsulated doxorubicin)
SOLTI Breast Cancer Research Group
Breast Cancer
01/16
01/16
NCT01959490: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Completed
2
16
US
trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, Pertuzumab, 2C4, Perjeta, docetaxel, RP 56976, Taxotere, TXT, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, doxorubicin, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, doxorubicin hydrochloride, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, paclitaxel, Anzatax, Asotax, TAX, Taxol, Bevacizumab, Avastin
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
11/16
03/17
NCT01912963: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Terminated
2
32
US
Pertuzumab, Perjeta, Trastuzumab, Herceptin, eribulin, eribulin mesylate, Halaven
Dana-Farber Cancer Institute, Eisai Inc., Genentech, Inc.
HER2-positive Breast Cancer, Metastatic Breast Cancer
12/16
12/16
NCT00875979 / 2008-008276-14: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Checkmark In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Apr 2014 - Apr 2014: In combination with pertuzumab in pts with HER2+ve, locally adv/mets BC
Checkmark Data
Jun 2010 - Jun 2010: Data
Completed
1/2
67
US, Canada, Europe
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg, Perjeta
Hoffmann-La Roche, Roche Pharma AG
Metastatic Breast Cancer
08/11
08/11
NCT00951665: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
107
US
paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
Genentech, Inc.
Metastatic Breast Cancer
02/12
06/13
NCT00934856 / 2009-010000-28: A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Checkmark SABCS 2013
Jan 2014 - Jan 2014: SABCS 2013
Checkmark Pooled P1 data
Dec 2011 - Dec 2011: Pooled P1 data
Completed
1/2
98
US, Europe
Docetaxel, Pertuzumab, Trastuzumab emtansine, T-DM1
Hoffmann-La Roche
Breast Cancer
10/13
10/13
Neohttp, NCT02345772: Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Terminated
1/2
4
US
fulvestrant 500 mg, fulvestrant, Docetaxel, Taxotere, Trastuzumab (H, 8mg/kg, Trastuzumab, Pertuzumab (P, 840 mg, Pertuzumab
Western Regional Medical Center
HER2-positive Breast Cancer, ER-positive Breast Cancer
11/15
11/15

Download Options